Telomir Raises $5.6M in PIPE at $1.16/Share; DeJoria Adds $1M
TELO sits 40% above its 52-week low of $0.888.
Summary
Telomir closed a $5.6M PIPE at $1.16/share, with John Paul DeJoria adding $1M. Proceeds fund the Phase 1/2 TNBC trial and working capital.
Key Events · Financing and Capital Events · TELO
-
PIPE Financing Closed
Issued 4,843,300 shares at $1.16 per share for ~$5.6M gross proceeds, a 5% discount to the 10-day VWAP.
-
DeJoria Increases Stake
Existing significant shareholder John Paul DeJoria invested an additional $1.0M in the private placement.
-
Placement Agent Warrants
Alexander Capital received warrants for 387,464 shares at $1.16 exercise price, expiring in 5 years, plus a 9% cash fee (~$455K).
-
Use of Proceeds
Funds primarily support the Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer and working capital.
Analysis · TELO · Life Sciences
A $5.6 million PIPE at $1.16 per share—a 5% discount to the 10-day VWAP—was closed by Telomir Pharmaceuticals, issuing 4,843,300 shares of common stock with no investor warrants or reset features. Existing significant shareholder John Paul DeJoria added $1.0 million, and the company granted placement agent Alexander Capital warrants for 387,464 shares at the same $1.16 strike. The capital extends the cash runway for the Phase 1/2 TNBC trial, but the new shares represent meaningful dilution for a company that recently flagged going-concern risk with cash only through Q1 2027.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1563 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TELO was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.2M. The 52-week trading range was $0.89 to $2.09. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.